Cerebral small vessel disease (CSVD) is a condition affecting the tiny blood vessels deep inside the brain, including small arteries, arterioles, and capillaries. It is one of the leading causes of cognitive decline, dementia, and stroke in older adults. Because the damage accumulates gradually and often silently, many people have significant CSVD on brain scans without realizing anything is wrong until symptoms like memory problems or difficulty walking become noticeable.
What Happens Inside the Brain
The small vessels in your brain do critical work: they deliver oxygen and nutrients to deep brain structures and maintain a protective barrier between your blood and brain tissue. In CSVD, the walls of these tiny vessels become damaged over time. The inner lining of the vessels stops functioning properly, allowing substances that normally stay in the bloodstream to leak into surrounding brain tissue. This triggers inflammation and gradually damages the white matter, the wiring that connects different brain regions.
The result is a slow, accumulating injury. White matter pathways degrade, small areas of brain tissue die from blocked blood flow, and the brain begins to shrink in affected regions. Because the damage is spread across deep brain structures rather than concentrated in one spot, it disrupts the networks your brain relies on for thinking speed, planning, balance, and movement.
The Two Main Types
Most cases of CSVD fall into two categories. The more common form, called arteriolosclerosis, targets the deep arteries that supply structures like the basal ganglia and deep white matter. It is closely tied to high blood pressure and diabetes. Years of elevated pressure physically damage these small vessel walls, thickening and stiffening them until blood flow is compromised.
The second form is cerebral amyloid angiopathy (CAA), in which a protein called beta-amyloid gradually builds up in the walls of small arteries near the brain’s surface. CAA becomes increasingly common with age and is also linked to Alzheimer’s disease. While arteriolosclerosis tends to cause damage deep in the brain, CAA more often affects the outer cortical regions and is a major cause of bleeding in the brain in older adults.
There are also rare inherited forms. The best known is CADASIL, caused by a mutation in the Notch3 gene. CADASIL can cause strokes, migraines, and dementia starting as early as a person’s 30s or 40s, and it is diagnosed through genetic blood testing.
How CSVD Appears on Brain Scans
CSVD is diagnosed primarily through MRI, which can reveal several characteristic patterns of damage. These markers often show up incidentally when a scan is done for another reason, and their presence and severity help doctors gauge how advanced the disease is.
- White matter hyperintensities: Bright patches on MRI scans indicating damaged white matter. They range from mild and patchy to extensive and widespread.
- Lacunes: Small cavities, typically a few millimeters to about 1.5 centimeters across, left behind where tiny strokes have killed brain tissue. They commonly appear in the basal ganglia and deep white matter.
- Microbleeds: Tiny deposits of blood that have leaked from damaged vessels. Their location matters: microbleeds deep in the brain point toward hypertension-related damage, while those near the brain’s surface suggest amyloid angiopathy.
- Enlarged perivascular spaces: The fluid-filled channels surrounding small blood vessels become visibly widened, suggesting the brain’s waste-clearance system is struggling.
- Brain atrophy: Overall shrinkage of brain tissue, particularly in areas like the hippocampus and frontal lobes.
Research from the Framingham Heart Study found that people with two or more of these markers on MRI had a 76% higher risk of developing dementia over a median follow-up of about seven years, compared to those with no markers. The more markers present, the greater the concern.
Symptoms and How They Progress
CSVD often starts without obvious symptoms. Early changes on brain scans can exist for years before a person notices anything wrong. When symptoms do appear, they typically involve thinking skills and movement, and they worsen gradually rather than striking suddenly.
The cognitive effects tend to hit processing speed and executive function hardest. You might find it takes longer to work through problems, that multitasking becomes difficult, or that planning and organizing feel more effortful than they used to. Memory problems develop too, but the slowing of mental processing is often the earliest and most prominent change. Lacunes in the thalamus are particularly associated with slower information processing, likely because they disrupt connections to the prefrontal cortex.
Walking and balance problems are another hallmark. People with CSVD often develop shorter steps, a wider stance, shuffling, stooped posture, reduced arm swing, and a general unsteadiness. These gait changes are closely linked to damage in the white matter near the brain’s fluid-filled ventricles. Because walking requires coordination between attention, spatial awareness, and motor control, the widespread network damage caused by CSVD makes it especially disruptive to gait.
CSVD is also a major cause of vascular dementia and contributes to roughly one in five strokes. In some cases, a small lacunar stroke is the first sign that draws medical attention to the underlying disease.
What Drives It: Risk Factors
High blood pressure is the single most important modifiable risk factor. The small, deep arteries of the brain are especially vulnerable to the physical stress of chronically elevated pressure. Diabetes, smoking, high cholesterol, and obesity also contribute, as do the same vascular risk factors that drive heart disease. Age is the strongest non-modifiable risk factor: CSVD becomes increasingly common after 60 and is found on MRI in the majority of people over 80.
Blood Pressure Control and Treatment
There is no cure for CSVD, and no medication specifically reverses the damage. Treatment centers on controlling the risk factors that drive progression, with blood pressure management at the top of the list.
A clinical trial in patients who had already experienced a lacunar stroke compared standard blood pressure lowering (targeting a systolic reading of 130 to 140 mm Hg) with intensive lowering (targeting 125 mm Hg or below). After two years, the intensive group showed less progression of white matter damage on MRI. This supports pushing blood pressure lower than traditional targets in people with established CSVD, though doctors balance this against the risk of symptoms like dizziness from blood pressure that drops too low.
Managing diabetes, quitting smoking, treating high cholesterol, and staying physically active are all part of the standard approach. Antiplatelet medications may be used after a lacunar stroke, though their role in preventing progression of the underlying disease is less clear.
Diet and Cognitive Protection
Diet is emerging as a meaningful factor. Research on the Mediterranean diet, which emphasizes fruits, vegetables, whole grains, fish, and olive oil, suggests it may help protect the brain even when CSVD is present. One study found that the expected relationship between CSVD markers on MRI and lower cognitive scores only held in people with low intake of healthy foods. Among those eating a diet rich in fruits, vegetables, and other components of the Mediterranean pattern, the same degree of brain damage was not associated with cognitive decline. In other words, a healthy diet appeared to build a kind of buffer, helping the brain maintain function despite the physical damage from CSVD.
This doesn’t mean diet can prevent or reverse the disease itself, but it suggests that what you eat may influence how well your brain copes with the damage that accumulates.
Retinal Imaging as an Early Window
Because the small blood vessels in the retina share many features with those in the brain, researchers have explored whether an eye exam could serve as an early screening tool for CSVD. Several retinal markers have shown associations with CSVD in studies, which makes biological sense since both vascular beds are exposed to the same systemic risk factors. However, a systematic review found that no retinal biomarker has yet proven reliable enough for clinical use. Studies have been too small and too inconsistent in their methods to establish clear diagnostic accuracy. For now, MRI remains the only dependable way to identify and monitor CSVD.